Study of T-lymphocyte subsets, nitric oxide, hexosamine and Helicobacter pylori infection in patients with chronic gastric diseases

Table 1 T-lymphocyte subsets in CG patients (^-x±s, %)

Lymphocyte	CG (n = 30)	Normal control (n = 20)
CD3+	60.7 ± 2.4b	68.3 ± 3.9
CD4+	35.8 ± 2.5b	43.0 ± 3.8
CD8+	25.2 ± 2.4a	26.4 ± 1.7
CD4+/CD8+	1.43 ± 0.15a	1.64 ± 0.18

^aP < 0.05,

^bP < 0.01, vs normal group

Table 2 T-lymphocyte subsets in CG patients with Hp infection (^-x±s, %)

lymphocyte	Hp (+) (n = 18)	Hp (-) (n = 12)
CD3+	59.7 ± 2.5b	62.2 ± 0.9
CD4+	34.8 ± 2.6a	36.9 ± 2.0
CD8+	25.3 ± 2.5	25.0 ± 2.3
CD4+/CD8+	1.42 ± 0.17	1.45 ± 0.12

^aP < 0.05,

^bP < 0.01, vs Hp (-)

Table 3 Pathological stages and T-lymphocyte subsets in CG (^-x±s,%)

Lymphocyte	Mild-moderate (n = 13)	Severe (n = 17)
CD3+	62.3 ± 1.7	59.5 ± 2.1b
CD4+	37.4 ± 1.8	35.4 ± 2.7a
CD8+	25.5 ± 2.1	24.9 ± 2.6
CD4+/CD8+	1.50 ± 0.13	1.40 ± 0.13a

^aP < 0.05,

^bP < 0.01, vs mild-moderate

Table 4 Changes in hexosamine levels in CG, PU + CG patients with Hp infection (^-x±s, mg/g)

	CG		PU + CG
	Hp (+) n = 18	Hp (-) n = 12	Hp (+) n = 24	Hp (-) n = 8
Hexosamine	40 ± 6	45 ± 7	39 ± 8	51 ± 7

^aP < 0.05, ^bP < 0.01, vs Hp (-)

Table 5 Changes in plasma NO, pathological stages and Hp infection in CG an d PU + CG (^-x±s, μg/L)

	CG	PU + CG
Hp (+)	2671 ± 258	3071 ± 398
Hp (-)	2282 ± 387	2579 ± 668
Mild-moderate	2328 ± 413	2403 ± 284
Severe	2656 ± 251	2880 ± 802

^aP < 0.05, ^bP < 0.01, vs Hp (-); ^cP < 0.05, vs severe.